Health and Human Services Secretary Robert F. Kennedy Jr. said Tuesday that he would remove the Centers for Disease Control and Prevention's recommendation for children and healthy pregnant women to ...

Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect ...

Patients with RSV hospitalization have increased odds of any acute cardiovascular event compared with COVID-19 hospitalizations.

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...